Business
Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that five posters featuring data on LIVMARLI™ (maralixibat)
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that five posters featuring data on LIVMARLI™ (maralixibat) oral solution will be presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting taking place virtually December 12-18, 2021.\n\nNew LIVMARLI Analyses\n\nAbstract #305: Response to treatment with maralixibat in Alagille syndrome is associated with improved health-related quality of life\nWednesday, December 15, 2021 from 1:30-2:15pm ET, Poster session II\nBy Binita M. Kamath, MBBChir, Pediatric Hepatologist, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada\n\nAbstract #297: Maralixibat treatment response is associated with improved health-related quality of life in patients with BSEP deficiency\nWednesday, December 15, 2021 from 1:30-2:15pm ET, Poster session II\nBy Kathleen M. Loomes, MD, Pediatric Gastroenterologist, Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia\n\nEncore presentations\n\nAbstract #304: Pruritus intensity is associated with cholestasis biomarkers and quality of life measures after maralixibat treatment in children with Alagille syndrome\nWednesday, December 15, 2021 from 1:30-2:15pm ET during Poster session II\nBy Binita M. Kamath, MBBChir, Pediatric Hepatologist, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada\n\nAbstract #548: An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome\nFriday, December 17, 2021 from 1:30-2:15pm ET, Poster session III\nBy Pam Vig, PhD, Head of R&D, Mirum Pharmaceuticals, Inc.\n\nAbstract #549: Gastrointestinal tolerability of maralixibat in patients with Alagille syndrome: An integrated analysis of short- and long-term treatment\nFriday, December 17, 2021 from 1:30-2:15pm ET, Poster session III\nBy Pam Vig, PhD, Head of R&D, Mirum Pharmaceuticals, Inc.\n\nThe abstracts are now available via the NASPGHAN website* and full presentations will be available at the start of the congress on December 12.\n\nAbout LIVMARLI™ (maralixibat) oral solution\nLIVMARLI™ (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the U.S. Food and Drug Administration for the treatment of...